Streetbeat News

Stock Prices

AHR

American Healthcare REIT (AHR) has announced that its FY24 guidance remains unchanged, with an expected NFFO per share of $1.18-$1.24, aligning with the estimated $1.21.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 9:32 pm

MSCI

Over the past 10 years, MSCI (NYSE:MSCI) has significantly outperformed the market, with an annualized return of 27.92%, turning a $1000 investment into $11,409.07 today. MSCI's market capitalization currently stands at $38.47 billion.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 9:30 pm

PHM

PulteGroup (NYSE:PHM) has significantly outperformed the market over the past decade, with an annualized return of 20.13%, turning a $100 investment into $620.36 today. The company's market capitalization stands at $24.48 billion.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 9:30 pm

LUXH

LuxUrban Hotels (LUXH) reported a Q1 2024 GAAP EPS of $(0.35), a 250% decrease from $(0.10) YoY. However, their sales of $29.101M exceeded the $27.675M estimate, marking a 27.56% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 9:21 pm

PSFE

Paysafe Ltd (NYSE:PSFE) reported Q1 earnings of 57 cents per share, surpassing the 10 cent analyst consensus. Sales reached $417.7 million, a 7% increase in total payment volume, beating the $408.25 million estimate. The Merchant Solutions segment saw an 11% revenue increase, while the Digital Wallets segment grew by 5%. CEO Bruce Lowthers highlighted strong Q1 revenue growth and reaffirmed the full-year 2024 revenue guidance of $1.688 billion to $1.712 billion. Following the announcement, PSFE shares rose 7.21% in after-hours trading.

Portfolio Pulse from Erica Kollmann

May 13, 2024 | 9:14 pm

GHSI

Guardion Health Sciences (NASDAQ:GHSI) reported a significant miss in Q1 EPS at $(3.71) versus the $(0.88) estimate and a slight miss in sales at $3.00M against the $3.12M estimate. This represents a 983.33% decrease in earnings and a 5.85% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 9:04 pm

CDNA

CareDx (NASDAQ:CDNA) has received mixed analyst ratings over the last three months, with a recent positive shift in price targets. Analysts from firms like Goldman Sachs and Stephens & Co. have raised their price targets, reflecting a bullish outlook. The average 12-month price target is now $15.4, up 24.9% from the previous $12.33. Despite challenges such as a -20.41% decline in revenue growth and below-average ROE and ROA, CareDx's net margin outperforms industry averages. The company, a provider of precision medicine for transplant patients, shows a prudent debt management with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 9:00 pm

LRCX

Lam Research (NASDAQ:LRCX) has significantly outperformed the market with an average annual return of 26.62% over the past 15 years, turning a $100 investment into $3,513.96 today. The company's market capitalization stands at $118.16 billion.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 9:00 pm

LULU

Lululemon Athletica (NASDAQ:LULU) has significantly outperformed the market over the past decade, with an average annual return of 22.82%, turning a $100 investment into $760.15 today. The company's market capitalization stands at $43.88 billion.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 9:00 pm

OBIO

Orchestra BioMed Holdings (NASDAQ:OBIO) reported Q1 EPS of $(0.38), surpassing the $(0.41) estimate, indicating a 7.32% beat and a 5% improvement from last year's $(0.40) per share. However, their Q1 sales of $620K fell short of the $940K estimate by 34.04%, marking a 46.74% decline from the previous year's $1.16M.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 9:00 pm